Migdal Insurance & Financial Holdings Ltd. Purchases Shares of 259,000 Gilead Sciences, Inc. $GILD

Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 259,000 shares of the biopharmaceutical company’s stock, valued at approximately $28,749,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. GoalVest Advisory LLC lifted its stake in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the third quarter valued at approximately $26,000. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences in the second quarter worth $27,000. Howard Hughes Medical Institute bought a new stake in shares of Gilead Sciences in the second quarter worth $30,000. Finally, Putney Financial Group LLC boosted its holdings in Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent research reports. Truist Financial assumed coverage on shares of Gilead Sciences in a research note on Monday, November 24th. They issued a “buy” rating and a $140.00 price target on the stock. The Goldman Sachs Group lifted their target price on Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research report on Thursday, January 8th. Wall Street Zen upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 3rd. Sanford C. Bernstein set a $135.00 price target on Gilead Sciences and gave the stock an “outperform” rating in a research report on Monday, December 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $135.00 price objective on shares of Gilead Sciences in a research note on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $133.28.

Insider Buying and Selling

In other Gilead Sciences news, EVP Deborah H. Telman sold 53,646 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the transaction, the executive vice president directly owned 43,676 shares of the company’s stock, valued at $5,365,596.60. This represents a 55.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the sale, the chief executive officer owned 581,203 shares of the company’s stock, valued at $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 136,757 shares of company stock valued at $16,951,612. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $124.14 on Wednesday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The business’s 50 day moving average price is $123.53 and its two-hundred day moving average price is $118.29. The company has a market cap of $154.02 billion, a PE ratio of 19.25, a price-to-earnings-growth ratio of 0.66 and a beta of 0.33. Gilead Sciences, Inc. has a twelve month low of $91.84 and a twelve month high of $128.70.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue was up 3.0% on a year-over-year basis. During the same period last year, the firm posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s payout ratio is currently 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.